Inari Medical, now part of Stryker, launches the all-new InThrill® Thrombectomy System, designed to address arteriovenous access and small vessel thrombus cases

Rhea-AI Summary

Inari Medical, a division of Stryker (NYSE:SYK), has launched the next-generation InThrill® Thrombectomy System, marking a significant advancement in small vessel and arteriovenous (AV) access thrombectomy procedures.

The new 8 French over-the-wire system features enhanced capabilities including increased radial force for better luminal wall apposition, offset single open mouth for optimized clot capture, internal struts for even clot distribution, and improved ergonomics. The first commercial case was successfully performed on May 19, 2025, at UPMC health care system by Dr. Joshua Pinter and Dr. Anish Ghodadra.

Positive

• First and only purpose-built small vessel and AV access thrombectomy system for full luminal clot removal
• Enhanced features including increased radial force and improved clot capture capabilities
• Successfully completed first commercial case with positive physician feedback

Negative

• None.

News Market Reaction – SYK

-0.03%

1 alert

-0.03% News Effect

On the day this news was published, SYK declined 0.03%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

PORTAGE, Mich., July 29, 2025 /PRNewswire/ -- Inari Medical, now part of Stryker (NYSE: SYK), a global leader in medical technologies, announced the launch of its next-generation InThrill Thrombectomy System, the first and only purpose-built small vessel and arteriovenous (AV) access thrombectomy system that can deliver fast, full luminal clot removal.

The second generation InThrill Thrombectomy System is an 8 French over-the-wire system comprising the InThrill thrombectomy catheter and the InThrill sheath. InThrill is built upon a familiar platform, optimized to become the standard for AV access and small vessel thrombectomy. Offering unmatched efficiency and clot removal, InThrill has distinctive features which include:

• Increased radial force for improved luminal wall apposition for optimized clot removal
• Offset single open mouth to optimize clot capture and removal
• Internal struts for even clot distribution within the element
• Redesigned backend to streamline ergonomics and improve the user experience.

On May 19, 2025, Dr. Joshua Pinter and Dr. Anish Ghodadra of the UPMC health care system performed the first commercial case using the new InThrill Thrombectomy System. "The next generation of InThrill has made our thrombectomies more effective and consistent than ever," said Dr. Pinter. "Inari's dedication to building a small vessel tool has changed our paradigm of treatment for AV access thrombectomy," added Dr. Ghodadra.

"The launch of the next-generation InThrill Thrombectomy System reflects our deep commitment to solving real-world challenges in vascular care," said Tim Lanier, president, Inari Division. "This latest innovation delivers new tools and enriches our work with physicians in the vascular space."

For more information, visit https://www.inarimedical.com/inthrill-thrombectomy-system

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

On February 19, 2025, Stryker acquired Inari Medical, a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases.

Media contact:
Sacha Ricarte
Director, Communications - Inari
Sacha.ricarte@stryker.com

Drs. Anish Ghodadra and Joshua Pinter are not paid consultants of Inari Medical. All views and opinions expressed here are their own and do not represent those of Inari Medical.

Indications for Use:
The InThrill Thrombectomy System is indicated for (1) the non-surgical removal of thrombi and emboli from blood vessels, including arteriovenous fistulae and arteriovenous grafts for dialysis access, and synthetic grafts and (2) injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel/graft. The InThrill Sheath is indicated for use as a conduit for the insertion of endovascular devices into the peripheral vasculature while minimizing blood loss associated with such insertions. The InThrill Thrombectomy System is intended for use in the peripheral vasculature. The InThrill Thrombectomy System is not intended for use in deep vein thrombosis (DVT) treatment.

Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product.

View original content to download multimedia:https://www.prnewswire.com/news-releases/inari-medical-now-part-of-stryker-launches-the-all-new-inthrill-thrombectomy-system-designed-to-address-arteriovenous-access-and-small-vessel-thrombus-cases-302515228.html

SOURCE Stryker

FAQ

What is the new InThrill® Thrombectomy System by Stryker (NYSE:SYK)?

The InThrill® Thrombectomy System is an 8 French over-the-wire system designed specifically for small vessel and arteriovenous access thrombectomy, featuring enhanced clot removal capabilities and improved ergonomics.

When was the first commercial case of Stryker's new InThrill® Thrombectomy System performed?

The first commercial case was performed on May 19, 2025, by Dr. Joshua Pinter and Dr. Anish Ghodadra at the UPMC health care system.

What are the key features of Stryker's next-generation InThrill® Thrombectomy System?

Key features include increased radial force for improved luminal wall apposition, offset single open mouth for optimized clot capture, internal struts for even clot distribution, and a redesigned backend for improved ergonomics.

How does the new InThrill® Thrombectomy System benefit vascular procedures?

The system provides fast, full luminal clot removal and is specifically designed for small vessel and arteriovenous access thrombectomy, offering improved effectiveness and consistency in procedures.